It should also be noted that exogenouslyadministered FGF2 may target other hepatic cells for its anti-fibrotic effects; Panet al. (41) demonstrated thatthe administration of recombinant low-molecular-weight FGF2 markedly reducedCCl4-induced liver fibrosis via the suppression of delta-like 1 (Dlk-1)expression in damaged hepatocytes, resulting in a decreased level of Dlk-1 protein inthe liver and serum to prevent HSC activation. This evidence concerns the gene DLK1 and Hepatic fibrosis.